MicroPort Scientific : ® NeuroTech Attends CSA&TISC to Promote APOLLO

Beijing, China - 3 July, 2015 - MicroPort NeuroTech (Shanghai) Co ("MicroPort® NeuroTech"), a wholly owned subsidiary of Shanghai MicroPort Medical (Group) Co ("MicroPort®"), recently attended the First Academic Meeting of Chinese Stroke Association and 2015 Tiantan International Stroke Conference ("CSA&TISC") held from June 26 to June 28 in Beijing, to promote our neurovascular device APOLLO Intracranial Stent System ("APOLLO").

During the conference which attracted several thousand experienced surgeons, Professor Zhongrong Miao of Beijing Tian Tan Hospital issued a report named "Result and Prospect of Registry in Endovascular Treatment for Intracranial Arterial Stenosis in China" in which he released the research result of APOLLO Balloon-Mounted Stent for Symptomatic Intracranial Artery Stenosis Registry Study in China: The rate of 30-day primary safety end point is 4.4%, better than the result from the SAMMPRIS, in which the rate in stent group is 14.7% and that in medical group is 5.8%.

"APOLLO is equipped with a rapid-exchange design which allows precise positioning and excellent radial force," said Bo Peng, MicroPort® Chief Marketing Office and the Executive Director of MicroPort® NeuroTech. "Such clinical outcome also showed the excellent surgical skills of surgeons in the 12 famous neuro-medical centers represented by Beijing Tian Tan Hospital, which proves that China now leads the world in Intracranial stents surgeries."

Independently designed and developed by MicroPort®, APOLLO was launched in the China market in 2015. It is China's first intracranial vascular stent for the treatment of ischemic cerebrovascular disease. It was awarded the second prize of Shanghai Scientific Progress Award in 2009 and was listed in the National Key New Products Scheme in 2011.

About MicroPort

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 18 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to: www.microport.com

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort's management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 2015 MicroPort Scientific Corporation